Wisevoter
U.S.

Medical Groups Issued Influenza Vaccine Recommendations

Experts provided new guidance for older adults amid federal court delays in the ACIP selection process.

Updated on Sept. 18, 2026 in COVID-19

Isometric editorial illustration showing a medical vial and syringe on a metal tray, representing clinical vaccine guidance.
Medical groups have released independent influenza vaccine guidance for older adults following a federal court's delay of the ACIP selection process. AI Illustration. Upload story photo >

Live Poll

Is October the best time for you to receive an annual flu vaccine?

Medical groups have issued independent influenza vaccine recommendations to fill the void left by a federal court ruling that halted the ACIP selection process in March 2026. This move aims to provide clear, science-based guidance for the upcoming respiratory disease season.

Why it matters

The Advisory Committee on Immunization Practices (ACIP) remains in a state of limbo following the federal court ruling, leaving a gap in national health policy. Experts are now providing alternative guidance to ensure the public receives timely information for fall vaccinations.

The FDA approved Moderna's mRNA influenza vaccine based on studies showing 25% higher effectiveness compared to standard-dose options for adults aged 50 to 64. Older adults are now advised to prioritize recombinant, adjuvanted, or high-dose vaccine options.

The players

William Schaffner

He is a professor of infectious diseases at Vanderbilt University Medical Center.

Paul A. Offit

He is an expert in immunology at the Children's Hospital of Philadelphia.

Aaron E. Glatt

He is a physician and infectious disease expert at Mount Sinai South Nassau.

Moderna

This biotechnology company developed and received FDA approval for a new mRNA-based influenza vaccine.

The details

While the FDA approved Moderna's mRNA influenza vaccine in August 2026 for those aged 50 to 64, initial recommendations for those 65 and older rely on comparative studies of existing high-dose and adjuvanted formulas. Medical groups now anticipate that the mRNA vaccine will see wider availability in large pharmacy chains as the season progresses.

Timeline

  1. March 2026: A federal judge blocked the selection process for the ACIP.

  2. August 2026: The FDA approved the new mRNA influenza vaccine.

  3. September 2026: Medical groups published current fall vaccination advice.

  4. October 2026: Experts recommend this window for flu vaccination.

  5. February/March 2027: Influenza activity often peaks during this period.

Deeper Dive

The ongoing suspension of the Advisory Committee on Immunization Practices marks a significant departure from standard national health governance. This situation forces medical organizations to provide independent guidance in place of the disrupted federal oversight program.

Patients aged 65 and older should consult their primary providers about selecting between recombinant, adjuvanted, or high-dose flu shots. Individuals should aim to get vaccinated by October to ensure they build immunity at least two weeks before peak exposure periods.

The takeaway

The current lack of federal committee guidance underscores the importance of consulting with local medical professionals to choose the most effective vaccine for your age group. Staying informed about clinical updates ensures that you remain protected during the upcoming flu season.

Further reading

For more information on seasonal health updates, visit the COVID-19 section.

Live Poll

Is October the best time for you to receive an annual flu vaccine?